Spacer Comparison In Adult Asthmatics
Phase 2
Completed
- Conditions
- Asthma
- Registration Number
- NCT00369993
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Spacers are used by people with respiratory diseases who have problems using MDIs (metered dose inhalers). This study used fluticasone propionate/salmeterol to look at the pharmacokinetic profiles produced by different spacers in their washed and un-washed states.
- Detailed Description
A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE™/ADVAIR™ 250 HFA MDI without spacer and with AeroChamber-Max spacer and VOLUMATIC™ both in their washed and unwashed states in adult subjects with mild or intermittent asthma.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The pharmacokinetic profile of fluticasone propionate (in particular the area under the curve to time t and the maximum concentration)
- Secondary Outcome Measures
Name Time Method The pharmacokinetic profile of salmeterol and the time to maximum concentration of fluticasone propionate
Trial Locations
- Locations (1)
GSK Investigational Site
🇳🇿Wellington, New Zealand